Data / Form D filings / Graviton BioScience Corp
Graviton BioScience Corp: Form D filings
Graviton BioScience Corp, a biotechnology company in New York, NY, filed 4 Form D notices with the SEC between 2021 and 2024. The latest, on February 14, 2024, reports $25 million sold of a $25 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 125 West End Ave, Suite 301, New York, NY, 10023
- Phone
- (332) 400-0444
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1847048
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 14, 2024 | New notice | $24,999,996 | $24,999,996 | 1 | Jan 31, 2024 | sec.gov | |
| Dec 4, 2023 | New notice | $50,000,000 | $39,819,496 | $10,180,504 | 11 | Dec 20, 2022 | sec.gov |
| Dec 4, 2023 | New notice | $24,999,998 | $24,999,998 | 1 | Nov 22, 2023 | sec.gov | |
| Feb 19, 2021 | New notice | $30,000,000 | $3,500,000 | $26,500,000 | 3 | Feb 4, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Samuel D Waksal | Executive Officer, Director, Promoter | |
| Bihua Chen | Director | |
| Jeremy D Levin | Director | |
| David D MacMillan | Director | |
| James D Boylan | Director | |
| Stelios D Papadopoulos | Director | |
| Ran D Nussbaum | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Feb 12, 2024 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Graviton BioScience Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.